Itraconazole topical - Fera Pharmaceuticals

Drug Profile

Itraconazole topical - Fera Pharmaceuticals

Alternative Names: Itraconazole suspension for topical application - Fairfield Clinical Trials/Fera Pharmaceuticals

Latest Information Update: 14 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fairfield Clinical Trials
  • Developer Fera Pharmaceuticals
  • Class Antifungals; Azoles; Chlorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Otitis externa
  • New Molecular Entity No

Highest Development Phases

  • No development reported Otitis externa

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 14 Aug 2015 No recent reports on development identified - Phase-II for Otitis externa in USA (Topical)
  • 22 Jul 2010 Phase-II clinical trials in Otitis externa in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top